India, June 2 -- Shares of Opus Genetics, Inc. (IRD) gained over 20% on Monday morning after the company announced positive topline results from LYNX-2, a pivotal Phase 3 clinical trial evaluating Phentolamine Ophthalmic Solution 0.75% for the treatment of significant, chronic night driving impairment in keratorefractive patients with reduced mesopic vision.
IRD is currently trading at $1.2100, up $0.2155 or 21.6692%, on the Nasdaq. The stock opened its trading at $1.6710 after closing Friday at $0.9945. The stock has traded between $0.6500 and $2.1800 in the past 52-week period.
The LYNX-2 study met its primary endpoint of a gain of three lines or more of distance vision improvement on a low contrast chart in low light conditions after 1...